Skip to content

Effect of Lidocaine Sprayed on Hemodynamics During Endotracheal Intubation

Effect of Lidocaine Sprayed on Direct Laryngoscopy and Trachea on Hemodynamics During Endotracheal Intubation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01737437
Enrollment
80
Registered
2012-11-29
Start date
2012-10-31
Completion date
2013-01-31
Last updated
2012-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurosurgical Patients

Brief summary

A previous study demonstrated topical lidocaine spray on the larynx and the trachea is effective in reducing hemodynamic response to laryngoscopy and endotracheal intubation. In clinical practice, blind oropharyngeal application of lidocaine without aiding direct laryngoscopy can not assured that sprayed lidocaine effectively reaches the larynx and trachea. Therefore, direct laryngoscopy should be necessary to reach topical lidocaine to correct sites. Unfortunately, direct laryngoscopy itself can affect hemodynamics during spraying lidocaine. In this study, we will investigate an effect of lidocaine sprayed on direct laryngoscopy and the tracheal mucosa on hemodynamic change throughout intubation.

Interventions

DRUGgroup C

0.9% normal saline was applied to trachea and laryngoscope blade

10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.

0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.

DRUGgroup LV

10% Lidocaine was applied on laryngoscope blade and trachea.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* aged 20-60 years, * ASA groups I or II

Exclusion criteria

* ASA III or IV, * hypertension, * anticipated difficult airway, and * severe coronary and cerebrovascular diseases

Design outcomes

Primary

MeasureTime frame
mean blood pressure, heart ratebaseline, at laryngoscope insertion, 60s after laryngoscope insertion, during intubation, one, two, three min after endotracheal intubation

Countries

South Korea

Contacts

Primary ContactSUE YOUNG LEE, MD
tndude49@hanmail.net82-10-9700-6509

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026